79389-39-2

Usage

Uses

Used in Pharmaceutical Synthesis:
(1S,2R)-2-methylcyclohexanamine hydrochloride is used as a building block in the synthesis of pharmaceuticals due to its unique stereochemistry and functional groups. Its specific arrangement and reactivity can contribute to the development of new drugs with targeted therapeutic effects.
Used in Organic Compounds Synthesis:
(1S,2R)-2-methylcyclohexanamine hydrochloride is also utilized as an intermediate in the synthesis of other organic compounds, where its cyclohexane ring and amine group can be further modified or incorporated into more complex molecules for various applications.
Used in Research and Chemical Manufacturing:
(1S,2R)-2-methylcyclohexanamine hydrochloride serves as a valuable reagent in research settings, where its properties can be explored for new chemical reactions or as a model compound for studying stereochemistry. Additionally, it may be used in chemical manufacturing processes to produce other valuable compounds or materials.

Upstream product

• 91603-26-8 (αS,1S,2R)-(-)-cis-2-Methyl-N-(1-phenylethyl)cyclohexanamin-hydrochlorid 
• 583-60-8 2-Methylcyclohexanone 
• 1071759-20-0 N-[(1R,2S)-2-methylcyclohexyl]-benzenemethanamine 
• 31887-88-4 N-(2-methylcyclohexylidene)-1-phenylmethanamine 
• 92761-49-4 (1S,Z)-N-((S)-2-methylcyclohexylidene)-1-phenylethanamine 
• 195251-76-4 E/Z-<2(RS)>-2-Methyl-N-(S-α-methylbenzyl)-cyclohexaneimine 
• 828291-16-3 E/Z-<2(RS)>-2-Methyl-N-(R-α-methylbenzyl)-cyclohexaneimine 
• 79265-63-7 ((1S,2R)-2-Methyl-cyclohexyl)-((S)-1-phenyl-ethyl)-amine; hydrochloride 
• 79265-63-7 ((1S,2R)-2-Methyl-cyclohexyl)-((S)-1-phenyl-ethyl)-amine; hydrochloride 

Downstream Products

• 302596-12-9 (S)-3-Benzyloxycarbonylamino-N-[(R)-1-((1S,2R)-2-methyl-cyclohexylcarbamoyl)-ethyl]-succinamic acid benzyl ester 
• 1227482-90-7 6-anilino-4-{[(1S,2R)-2-methylcyclohexyl]amino}nicotinamide 
• 1227487-28-6 6-chloro-4-{[(1S,2R)-2-methylcyclohexyl]amino}nicotinamide 
• 1227487-01-5 6-chloro-4-{[(1S,2R)-2-methylcyclohexyl]amino}nicotinic acid 
• 1227486-47-6 ethyl 6-chloro-4-{[(1S,2R)-2-methylcyclohexyl]amino}nicotinate 
• 1263419-19-7 4-((1S,2R)-2-methylcyclohexylamino)-6-nitropyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1263420-12-7 4-((1S,2R)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1263419-14-2 4-((1S,2R)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1263419-20-0 4-((1S,2R)-2-methylcyclohexylamino)-6-nitropyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1263419-21-1 6-amino-4-((1S,2R)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carboxamide 

Relevant academic research and scientific papers

Evaluating dynamic kinetic resolution strategies in the asymmetric hydrosilylation of cyclic ketimines

Attempts at performing dynamic kinetic resolution on a series of cyclic ketimines by making use of an asymmetric organocatalysed hydrosilylation gave modest conversion and moderate to good enantioselectivities. In the case of α-tetralone derivatives, the use of an N-benzyl protecting group was found to be crucial in obtaining enhanced levels of selectivity.

PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS

The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.

Pyrrolopyrazinyl Urea Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R1, R2, R3, R4, and R5 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Asymmetric Reductive Amination of Cycloalkanones, 2. Synthesis and Absolute Configuration of 2-Substituted Cyclohexanamines

Asymmetric synthesis of 2-substituted cyclohexanamines from racemic cyclohexanones by means of reductive amination in a three-step procedure is described.Condensation of the ketones 5 with the optically active auxiliary amines 6 leads to the imines 7, which are hydrogenated to the secondary amines 8 with Raney nickel.Hydrogenolysis with palladium-on-charcoal yields the primary amines 9.With Raney nickel as catalyst the synthesis of the amines 8 and 9 runs with high chemical yield under complete diastereomeric and high grade enantiomeric control, respectively.Enantiomeric excess is determined via the diastereomeric acylamines 10 by means of HPLC.Stereochemical analysis including the absolute configuration of 8 and 9 is performed with 1H, 13C NMR spectroscopy, via the CD of the salicylidenes 11 and the X-ray spectrum of the amine 9c. - Reaction mechanism is investigated via the partially deuterated amine 13 to come up as a kinetically controlled asymmetric hydrogenation combined with a thermodynamically controlled transformation.

ASYMMETRIC SYNTHESIS OF CIS-2-SUBSTITUTED CYCLOHEXANAMINES WITH HIGHT OPTICAL PURITY

Asymmetric reductive amination of racemic 2-substituted cyclohexanones (R= methyl, ethyl, phenyl, benzyl) using optically active 1-phenyl-ethylamines yields optically active cis-cyclohexanamines.